ImmunityBio (NASDAQ:IBRX) Stock

IMMUNITYBIO INC

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

ImmunityBio Inc

First BanCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBP#NYSE">FBP</a>) has outperformed the market over the past 15 years by 15.29% on an annualized basis producing an average annual return of 27.71%. Currently, First BanCorp has a market capitalization of $3.54 billion. 
Buying $100 In FBP: If an investor had bought $100 of FBP stock 15 years ago, it would be worth $3,379.04 today based on a price of $21.93 for FBP at the time of writing.
<h3>First BanCorp's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751585416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In First BanCorp 15 Years Ago Would Be Worth This Much Today

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 3.67% on an annualized basis producing an average annual return of 12.17%. Currently, Gilead Sciences has a market capitalization of $138.95 billion. 
Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,708.95 today based on a price of $111.70 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751584511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GILD

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today

RCL continues early strength after the alert
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/03200938/Screenshot-2025-07-03-at-4.01.37%E2%80%AFPM-1011x1024.png" alt="" class="wp-image-15328" /></figure>
Royal Caribbean (RCL) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 11:07 AM on July 3rd, a significant trading signal occurred for Royal Caribbean (RCL) as it demonstrated a Power Inflow at a price of $331.57. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Royal's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Royal's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for RCL,<a href="https://benzinga.grsm.io/register174"> Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025</a>
After Market Close UPDATE:
The price at the time of the Power Inflow was $331.57. The returns on the High price ($334.48) and Close price ($334.26) after the Power Inflow are respectively 0.9% and 0.8%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past performance is not indicative of future results

Equities

Technicals

Opinion

Signals

Royal Caribbean Cruises Stock Up 0.9% After Key Trading Signal

Senra, a Southern California startup founded by ex‑<a href="https://www.benzinga.com/news/25/04/44865115/figure-ai-shakes-silicon-valley-with-39-5b-valuation-200000-robots-promised-by-2029-beating-out-spacex-and-openai">SpaceX</a> engineers Jordan Black and Benjamin Shanahan, is stepping into the spotlight after<a href="https://www.senrasystems.us/media/announcing-our-series-a"> announcing</a> on June 18 a $25 million Series A aimed at revamping critical <a href="https://www.benzinga.com/markets/tech/25/06/45965573/openai-wins-200-million-us-defense-contract-for-ai-warfare-capabilities-as-the-company-looks-to-raise-40-billion">U.S. defense</a> manufacturing.
The startup focuses on wire harnesses, which are bundles of wires and connectors that deliver power and data across cutting‑edge hardware like autonomous drones, satellites, and reusable rockets.
According to Senra, investors include Dylan Field, co‑founder and CEO of Figma, alongside top‑tier firms CIV, Andreessen Horowitz via its American Dynamism practice, Sequoia Capital, Founders Fund, General Catalyst, and 8VC, signaling a strategic push to bolster national supply chains.
Don't Miss:
<ul class="wp-block-list">
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
</ul>
<h2 class="wp-block-heading">Wire Harnesses, the Hidden Bottleneck in Defense Hardware</h2>
According to Senra, wire harnesses are often the last item designed and the first to need installation, yet they remain essential to system reliability. Many manufacturers still depend on outdated tools such as Excel, Visio, and PDFs, combined with manual, error-prone assembly processes.
This, the company says, has led to extended lead times, inconsistent product quality, and mounting bottlenecks in industries that rely on speed and precision. As demand rises and the skilled labor pool declines, legacy suppliers are increasingly unable to keep pace.
Black told<a href="https://www.bloomberg.com/news/articles/2025-06-18/ex-spacex-staffers-raise-cash-for-us-manufacturing-startup"> Bloomberg</a> that harnesses are "unsung villains" in American manufacturing because outdated production methods persist. U.S. manufacturers still depend on manual techniques like wire stretching on wooden peg boards, processes that remained unchanged since the Cold War era.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation.&nbsp;</a>
"It's crazy. They make wire harnesses the same way they did during the Cold War," General Catalyst Managing Director Paul Kwan told Bloomberg. Harness production issues caused the deadly Apollo 1 fire 1967 and the Apollo 13 mishap three years later, as well as recalls by carmakers such as Mercedes, Kia, and Nissan.
Senra addresses a growing crisis in U.S. manufacturing readiness, intensified by increased demand from firms like SpaceX and Anduril. Field told Bloomberg that he never knew he "was so excited about wire harnessing" until he met Black, emphasizing the founders' passion and the strategic importance of their tech.
<h2 class="wp-block-heading">A Strategic Move in a Bigger Manufacturing Wave</h2>
According to Bloomberg, Senra currently manufactures about 1,000 harnesses monthly but aims to scale to 10,000 by next year. Plans include opening a 100,000‑square‑foot facility in Southern California equipped with custom wire‑strippers, plus a proprietary software platform to streamline design, supply‑chain tracking, and quality control.
See Also: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a>
Senra joins a growing cohort of startups working to modernize automotive, defense, healthcare, and industrial supply chains, alongside Re:Build Manufacturing, Hadrian Automation, and Nominal, Bloomberg reports. The company says its wire harnesses are now used in a wide range of applications, supporting industries that power and protect everyday life across the U.S.
According to Senra, its stated mission is to become the most dependable harness provider globally by delivering with consistency, precision, and no operational surprises.
The $25 million injection will scale operations and also enable the rollout of Senra's proprietary design software, set for release later this year. By solving a critical hardware bottleneck, Senra is positioning itself as a strong partner in America's high‑tech defense infrastructure.
Read Next: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Image: Shutterstock

Ex-SpaceX Team's $25M Startup Is Rewiring The Future Of U.S. Defense—They Still Build These Things 'The Same Way They Did During The Cold War'

Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) has outperformed the market over the past 5 years by 2.51% on an annualized basis producing an average annual return of 17.3%. Currently, Liberty Energy has a market capitalization of $1.94 billion. 
Buying $1000 In LBRT: If an investor had bought $1000 of LBRT stock 5 years ago, it would be worth $2,119.30 today based on a price of $11.97 for LBRT at the time of writing.
<h3>Liberty Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751583618_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LBRT

Here's How Much You Would Have Made Owning Liberty Energy Stock In The Last 5 Years

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) has outperformed the market over the past 5 years by 22.27% on an annualized basis producing an average annual return of 37.06%. Currently, NRG Energy has a market capitalization of $30.98 billion. 
Buying $1000 In NRG: If an investor had bought $1000 of NRG stock 5 years ago, it would be worth $4,795.34 today based on a price of $158.45 for NRG at the time of writing.
<h3>NRG Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751582711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In NRG Energy 5 Years Ago Would Be Worth Today

Shaquille O'Neal has enough money to hire a private chef, dine at Michelin-starred restaurants every night, and snack on gold-dusted truffles if he really wanted to. But he's not chasing foie gras and fig reductions.
He may be <a href="https://www.benzinga.com/personal-finance/25/03/44380108/trust-me-im-reading-what-hes-doing-every-day-nba-legend-shaq-with-a-500-million-net-worth-swears-by-warren-buffetts-investing-wisdom">worth half a billion</a>, but his palate is still planted firmly in the drive-thru. During a 2022 <a href="https://youtu.be/uLjK50xc9XI?si=EFaCvUAdX3F3RjX7">appearance on "The Late Show with Stephen Colbert,"</a> Shaq waved off the fine-dining lifestyle with a shrug and a line that couldn't have been more on-brand:
"I don't like rich people food," he said. "Like hors d'oeuvres."
"Us regular people, we like chicken wings."
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. </a></li>
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
</ul>
He followed it up with the kind of menu only Shaq could deliver:
"I don't like going to these parties and the caviar. I don't like all that stuff. I want chicken wings, pizza, and chips."
This wasn't just a punchline. It's personal. Shaq was there to promote his cookbook "Shaq's Family Style: Championship Recipes for Feeding Family and Friends"—a collection inspired by the food he actually eats, not the stuff that comes with edible flowers and a side of foam.
"I have three chefs—two Matts and a guy named Alex," he told host Stephen Colbert. But during the pandemic, with nothing to do, he asked them to teach him how to cook. "Before you knew it, I was cooking 10 to 15 dishes," he said.
His food philosophy? Straightforward:
"My favorite diet is called ‘no diet.'"
And if he eats something he's not supposed to? "I guess I'll start my diet tomorrow."
Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a>
That same honesty spills into his business strategy. Shaq doesn't just eat like a regular guy—he invests like one. If he's putting money behind a brand, it's probably because it serves something you'd find in his kitchen.
He owns nine Papa John's franchises and sits on the company's board. He once <a href="https://www.benzinga.com/25/05/45601247/shaq-owned-155-five-guys-but-had-no-clue-how-to-run-them-so-he-turned-to-a-mcdonalds-manager-who-hooked-him-up-during-his-nba-days-into-a-partner">owned 155 Five Guys restaurants</a>—about 10% of the chain—and added <a href="https://www.benzinga.com/startups/24/12/42468734/nba-legend-shaq-owned-17-auntie-annes-franchises-but-sold-them-after-realizing-black-people-dont-like-pretzels-that-much">Auntie Anne's Pretzels</a> to the lineup before eventually selling his stakes. He also owns a <a href="https://www.benzinga.com/personal-finance/25/03/44207096/shaq-said-his-krispy-kreme-store-was-likely-burned-down-by-homeless-trying-to-stay-warm-im-not-gonna-be-putting-charges-on-homeless-people">Krispy Kreme location in Atlanta</a>, which he's said he plans to expand.
And then there's Big Chicken, the fast-casual spot he co-founded that serves—you guessed it—Shaq-sized portions of fried chicken, mac and cheese, and massive cookies. If you want to eat like Shaq, you actually can. Just don't expect foie gras.
So while some celebrities attach their names to tequila bottles or skincare lines, Shaq keeps it simple: wings, pizza, and chips. And if the business happens to be delicious too? Even better.
Read Next:
<ul class="wp-block-list">
<li>Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Image: Shutterstock

Personal Finance

NBA Legend Shaq Says 'I Don't Like Rich People Food' Despite $500 Million Net Worth: 'I Want Chicken Wings, Pizza, and Chips'

General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) has outperformed the market over the past 5 years by 1.26% on an annualized basis producing an average annual return of 16.05%. Currently, General Motors has a market capitalization of $51.03 billion. 
Buying $1000 In GM: If an investor had bought $1000 of GM stock 5 years ago, it would be worth $2,055.58 today based on a price of $52.81 for GM at the time of writing.
<h3>General Motors's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751581816_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In General Motors 5 Years Ago Would Be Worth This Much Today

CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) has outperformed the market over the past 15 years by 10.06% on an annualized basis producing an average annual return of 22.49%. Currently, CoStar Group has a market capitalization of $34.64 billion. 
Buying $1000 In CSGP: If an investor had bought $1000 of CSGP stock 15 years ago, it would be worth $21,002.56 today based on a price of $82.12 for CSGP at the time of writing.
<h3>CoStar Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751580918_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CSGP

Here's How Much You Would Have Made Owning CoStar Group Stock In The Last 15 Years

In the current market session, Cognex Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) share price is at $32.29, after a 1.49% drop. Over the past month, the stock increased by 7.54%, but over the past year, it actually decreased by 31.22%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1751580019_0.png" alt="Past Year Chart" />

<h3>Cognex P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 41.59 in the Electronic Equipment, Instruments &amp; Components industry, Cognex Inc. has a higher P/E ratio of 47.52. Shareholders might be inclined to think that Cognex Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1751580019_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

CGNX

P/E Ratio Insights for Cognex

Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) has outperformed the market over the past 10 years by 9.8% on an annualized basis producing an average annual return of 21.63%. Currently, Wix.com has a market capitalization of $9.15 billion. 
Buying $1000 In WIX: If an investor had bought $1000 of WIX stock 10 years ago, it would be worth $6,961.44 today based on a price of $164.29 for WIX at the time of writing.
<h3>Wix.com's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751579114_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Wix.com 10 Years Ago Would Be Worth This Much Today

Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) has outperformed the market over the past 10 years by 8.53% on an annualized basis producing an average annual return of 20.36%. Currently, Parker Hannifin has a market capitalization of $92.60 billion. 
Buying $1000 In PH: If an investor had bought $1000 of PH stock 10 years ago, it would be worth $6,218.33 today based on a price of $719.15 for PH at the time of writing.
<h3>Parker Hannifin's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751578220_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Parker Hannifin 10 Years Ago Would Be Worth This Much Today

Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) has outperformed the market over the past 5 years by 3.89% on an annualized basis producing an average annual return of 18.68%. Currently, Ulta Beauty has a market capitalization of $21.47 billion. 
Buying $100 In ULTA: If an investor had bought $100 of ULTA stock 5 years ago, it would be worth $228.61 today based on a price of $477.79 for ULTA at the time of writing.
<h3>Ulta Beauty's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751577312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ULTA

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

In a major political victory, President Donald Trump secured the first legislative triumph of his second term, as House Republicans passed his <a href="https://www.benzinga.com/news/financing/25/07/46215975/trumps-big-beautiful-bill-offers-seniors-a-6000-bonus-tax-deduction-heres-how-you-qualify-for-the-benefit">sweeping domestic agenda bill</a> on Thursday, just ahead of the July 4 holiday.
Dubbed the "One Big, Beautiful Bill," the $3.3 trillion package includes a mix of tax cuts, military and border security boosts, and the steepest federal safety net reductions in decades, CNN <a href="https://www.cnn.com/2025/07/03/politics/trump-agenda-passed-congress">reports</a>.
The Senate had approved the legislation earlier in the week, and despite opposition from two House Republicans, the bill cleared both chambers largely along party lines. GOP leaders — Speaker Mike Johnson and Senate Majority Leader John Thune — overcame internal resistance to deliver on Trump's top campaign promises.
The bill makes permanent the 2017 individual tax cuts and doubles the standard deduction, a move the Tax Policy Center says will save the average filer about $2,900 in 2026. Seniors will temporarily get an added $6,000 deduction, but Trump's campaign pledge to end Social Security <a href="https://www.benzinga.com/news/financing/25/07/46215083/how-trumps-big-beautiful-bill-impacts-snap-medicaid-taxes-and-student-loans">taxes was dropped.</a>
Also Read: <a href="https://www.benzinga.com/news/politics/25/07/46237506/trump-says-jerome-powell-should-resign-immediately-after-fhfa-director-alleges-fed-chair-lied-about-2-5-billion-renovation-plan">Trump Says Jerome Powell Should &#8216;Resign Immediately&#8217; After FHFA Director Alleges Fed Chair Lied About $2.5 Billion Renovation Plan</a>
At the heart of the package are aggressive changes to Medicaid and SNAP. The bill imposes new work requirements and paperwork hurdles that the Congressional Budget Office estimates will cause 12 million people to lose Medicaid coverage, CBS News <a href="https://www.cbsnews.com/news/comparing-medicaid-cuts-house-senate-trump-big-beautiful-bill/">reports</a>. States will shoulder more program costs and face penalties for high payment errors.
Regarding education, the bill caps graduate loans and phases out popular programs, including Grad PLUS and subsidized loans. Forgiveness options shrink, and new borrowing limits will hit middle-class families the hardest.
Yet, the bill also introduces a pilot program called "Trump Accounts." Every baby born from 2025 through 2028 will receive a $1,000 stock market account seeded by the federal government, with parents allowed to contribute up to $5,000 annually.
Democrats, with Minority Leader Hakeem Jeffries at the helm, criticized the bill as favoring the wealthy while placing undue burdens on vulnerable communities.
Jeffries vowed to make the bill the centerpiece of 2026 midterm campaigns, citing $295 billion in SNAP cuts and a $1 trillion Medicaid rollback.
Despite the backlash, Trump and GOP leaders are already celebrating what they view as a defining legislative moment — a bet that the benefits will outweigh the political risks come election season.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/07/46252465/cybertruck-dreams-shatter-as-musks-250k-goal-unravels">Cybertruck Dreams Shatter As Musk&#8217;s 250K Goal Unravels</a></li>
</ul>
Photo: Shutterstock

Politics

Trump's $3.3 Trillion Bill Passes: Will Vulnerable Americans Pay The Price?

<h3>Gainers</h3>
<ul>
<li>EpicQuest Education Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEIQ#NASDAQ">EEIQ</a>) stock increased by 13.9% to $0.55 during Thursday's after-market session. The company's market cap stands at $6.5 million. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) stock moved upwards by 6.06% to $0.81. The company's market cap stands at $82.7 million. </li>
<li>INNEOVA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INEO#NASDAQ">INEO</a>) stock rose 5.73% to $1.29. The market value of their outstanding shares is at $11.1 million. </li>
<li>Crown Crafts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWS#NASDAQ">CRWS</a>) shares moved upwards by 5.08% to $3.1. The market value of their outstanding shares is at $30.5 million. </li>
<li>Twin Hospitality Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWNP#NASDAQ">TWNP</a>) shares increased by 4.98% to $4.84. The market value of their outstanding shares is at $264.7 million. </li>
<li>Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) stock moved upwards by 4.85% to $3.67. The company's market cap stands at $44.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fenbo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEBO#NASDAQ">FEBO</a>) shares declined by 9.3% to $0.98 during Thursday's after-market session. The market value of their outstanding shares is at $10.3 million. </li>
<li>Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) stock fell 6.14% to $1.53. The company's market cap stands at $89.5 million. </li>
<li>Lazydays Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) shares fell 5.93% to $0.23. The market value of their outstanding shares is at $27.0 million. </li>
<li>Jinxin Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMI#NASDAQ">NAMI</a>) shares fell 5.41% to $1.05. The company's market cap stands at $72.6 million. </li>
<li>OneWater Marine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEW#NASDAQ">ONEW</a>) shares decreased by 5.0% to $14.25. The company's market cap stands at $217.6 million. </li>
<li>American Outdoor Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOUT#NASDAQ">AOUT</a>) shares declined by 5.0% to $10.09. The company's market cap stands at $134.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AOUT

CRWS

EEIQ

FEBO

FOSL

GORV

INEO

ISPO

NAMI

ONEW

PRPL

TWNP

12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock increased by 13.8% to $4.46 during Thursday's after-market session. The company's market cap stands at $13.1 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares increased by 11.11% to $0.45. The company's market cap stands at $20.7 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares rose 10.29% to $6.43. The company's market cap stands at $100.6 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock rose 9.85% to $0.7. The company's market cap stands at $74.9 million. </li>
<li>Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) stock rose 9.17% to $14.76. The market value of their outstanding shares is at $613.0 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares moved upwards by 9.02% to $1.45. The company's market cap stands at $78.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock declined by 16.6% to $2.36 during Thursday's after-market session. The company's market cap stands at $5.5 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 14.97% to $19.55. The company's market cap stands at $5.1 billion. As per the news, the H1 earnings report came out 3 days ago. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock decreased by 9.09% to $10.11. The company's market cap stands at $6.1 million. </li>
<li>Coherus Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares declined by 8.62% to $0.74. The company's market cap stands at $92.1 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares decreased by 6.38% to $0.87. The market value of their outstanding shares is at $2.8 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares decreased by 5.87% to $0.71. The market value of their outstanding shares is at $13.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBNX

CGTX

CHRS

INDP

LIXT

NTHI

PROK

SONN

TRIB

WINT

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) stock increased by 9.4% to $2.57 during Thursday's after-market session. The company's market cap stands at $5.6 million. </li>
<li>FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) shares moved upwards by 7.92% to $0.72. The company's market cap stands at $6.4 million. </li>
<li>GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) stock rose 7.81% to $27.3. The market value of their outstanding shares is at $3.4 billion. </li>
<li>Eshallgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) stock moved upwards by 7.31% to $0.88. The market value of their outstanding shares is at $22.9 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) stock moved upwards by 6.68% to $3.51. The market value of their outstanding shares is at $109.5 million. </li>
<li>iPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) stock rose 5.91% to $0.68. The company's market cap stands at $21.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>HUHUTECH International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUHU#NASDAQ">HUHU</a>) shares decreased by 8.0% to $6.99 during Thursday's after-market session. The company's market cap stands at $128.3 million. </li>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) shares fell 6.28% to $0.63. The company's market cap stands at $9.9 million. </li>
<li>MingZhu Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) stock decreased by 5.4% to $0.96. The company's market cap stands at $75.1 million. </li>
<li>Controladora Vuela (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) stock decreased by 5.2% to $4.56. The market value of their outstanding shares is at $554.3 million. </li>
<li>BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) shares decreased by 4.97% to $14.92. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Highway Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIHO#NASDAQ">HIHO</a>) stock decreased by 4.94% to $1.54. The company's market cap stands at $7.2 million. As per the news, the Q4 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EHGO

GLXG

HIHO

HUHU

IPDN

NEOV

VLRS

YGMZ

12 Industrials Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Youxin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YAAS#NASDAQ">YAAS</a>) stock increased by 11.0% to $0.51 during Thursday's after-market session. The company's market cap stands at $15.2 million. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) stock moved upwards by 6.69% to $0.43. The market value of their outstanding shares is at $16.7 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) shares rose 5.91% to $2.15. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) shares rose 5.17% to $4.88. The market value of their outstanding shares is at $6.9 million. </li>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) shares increased by 4.6% to $1.59. The market value of their outstanding shares is at $22.8 million. </li>
<li>MultiSensor AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSAI#NASDAQ">MSAI</a>) shares rose 4.58% to $0.68. The company's market cap stands at $21.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BitMine Immersion Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) shares declined by 10.4% to $121.01 during Thursday's after-market session. The market value of their outstanding shares is at $354.7 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares decreased by 8.02% to $0.39. The market value of their outstanding shares is at $11.3 million. </li>
<li>Bridgeline Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>) stock fell 6.09% to $1.39. The company's market cap stands at $17.1 million. </li>
<li>Locafy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) shares declined by 5.65% to $5.35. The company's market cap stands at $7.6 million. </li>
<li>Forward Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORD#NASDAQ">FORD</a>) shares decreased by 5.13% to $7.4. The company's market cap stands at $7.8 million. </li>
<li>Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) shares decreased by 5.0% to $2.47. The market value of their outstanding shares is at $76.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLIN

BMNR

BNAI

CMBM

CMTL

FORD

GREE

LCFY

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

OBLG

SVRE

YAAS

12 Information Technology Stocks Moving In Thursday's After-Market Session

Throughout the last three months, 7 analysts have evaluated Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.71, along with a high estimate of $22.00 and a low estimate of $13.00. A decline of 18.56% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1751576451_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Chemours. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Chemours. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Chemours compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Chemours's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Chemours's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Chemours analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Chemours: A Closer Look</h2>
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal &amp; Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
<h3>A Deep Dive into Chemours's Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3M period, Chemours showcased positive performance, achieving a revenue growth rate of 0.44% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Chemours's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.29% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Chemours's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.68%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Chemours's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.05%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Chemours's debt-to-equity ratio stands notably higher than the industry average, reaching 7.57. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For Chemours's Future

Simon Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) has outperformed the market over the past 5 years by 5.6% on an annualized basis producing an average annual return of 20.39%. Currently, Simon Property Group has a market capitalization of $54.40 billion. 
Buying $1000 In SPG: If an investor had bought $1000 of SPG stock 5 years ago, it would be worth $2,418.98 today based on a price of $166.74 for SPG at the time of writing.
<h3>Simon Property Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751576425_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Simon Property Group 5 Years Ago Would Be Worth This Much Today

Press Releases

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry

Comments

ImmunityBio

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL